Refractory Anaplastic Large Cell Lymphoma
Drug | Drug Name | Drug Description |
---|---|---|
DB08865 | Crizotinib | A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB02379 | Beta-D-Glucose | 1 | Completed | 1 |
DB00958 | Carboplatin | 1 | Completed | 1 |
DB14707 | Cemiplimab | 1 | Recruiting | 1 |
DB00531 | Cyclophosphamide | 1 | Completed | 1 |
DB00531 | Cyclophosphamide | 1 | Recruiting | 1 |
DB00773 | Etoposide | 1 | Completed | 1 |
DB14999 | Human interferon beta | 1 | Recruiting | 1 |
DB01181 | Ifosfamide | 1 | Completed | 1 |
DB14867 | Parsaclisib | 1 | Recruiting | 1 |
DB06176 | Romidepsin | 1 | Completed | 1 |
DB06176 | Romidepsin | 1 | Recruiting | 1 |
DB11119 | Sodium iodide | 1 | Recruiting | 1 |
DB17404 | AFM-13 | 1 / 2 | Active Not Recruiting | 1 |
DB18674 | Acimtamig | 1 / 2 | Active Not Recruiting | 1 |
DB08865 | Crizotinib | 1 / 2 | Completed | 1 |
DB00531 | Cyclophosphamide | 1 / 2 | Active Not Recruiting | 1 |
DB01073 | Fludarabine | 1 / 2 | Active Not Recruiting | 1 |
DB09037 | Pembrolizumab | 1 / 2 | Active Not Recruiting | 2 |
DB06813 | Pralatrexate | 1 / 2 | Active Not Recruiting | 1 |
DB06176 | Romidepsin | 1 / 2 | Active Not Recruiting | 1 |
DB00135 | Tyrosine | 1 / 2 | Completed | 1 |
DB09035 | Nivolumab | 2 | Active Not Recruiting | 1 |
DB06132 | Nivolumab | 2 | Terminated | 1 |
DB09035 | Nivolumab | 2 | Terminated | 1 |
DB06306 | Onalespib | 2 | Terminated | 1 |
DB13896 | Talimogene laherparepvec | 2 | Active Not Recruiting | 1 |